Mindray Downgraded to Neutral - Analyst Blog
03 Gennaio 2013 - 12:30PM
Zacks
We downgrade our recommendation on
Mindray Medical International Limited (MR) to
Neutral. Its third-quarter 2012 adjusted (excluding one-time
expenses other than stock-based compensation expense) earnings per
share of 39 cents missed the Zacks Consensus Estimate of 41
cents.
Revenues were up sharply 17.7% year
over year to $257.1 million, in the third quarter, missing the
Zacks Consensus Estimate of $268 million. During the reported
quarter, Mindray recorded ex-China sales of $139.4 million, up
11.6% year over year. Revenues in China increased 25.9% year over
year to $117.7 million in the reported quarter. The company
performed well in emerging markets.
Mindray is a bellwether in the
Chinese MedTech industry with a solid international presence. A key
distinction with domestic competitors is that the majority of
Mindray’s products have CE Mark and/or Food and Drug Administration
(“FDA”) clearance.
Mindray maintains a decent product
pipeline. New products contribute in a major way to Mindray’s
revenues. The company typically introduces a dozen or so fresh
products each year.
The company has entered the premium
segment globally, where its competitive advantage is still unclear.
Also, on the negative side, health care reform in China and the
U.S. may reduce demand for Mindray’s products. Competition is
fierce and leads to price erosion over time.
Mindray’s competitors, in different
niche segments, include GE Healthcare, a part of General
Electric (GE), Philips (PHG) and
Siemens (SI). We are currently Neutral on the
stock. The stock currently retains a Zacks #4 Rank, which
translates into a short-term “Sell” rating.
GENL ELECTRIC (GE): Free Stock Analysis Report
MINDRAY MEDICAL (MR): Free Stock Analysis Report
KONINKLIJKE PHL (PHG): Free Stock Analysis Report
SIEMENS AG-ADR (SI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Lug 2023 a Lug 2024